Pfizer Inc. (PFE) announced encouraging top-line safety and immunogenicity results on Monday from sub-study B of their ongoing pivotal Phase 3 MONeT trial, which evaluates the company's RSV vaccine, ABRYSVO, in immunocompromised adults.
The investigation encompassed four cohorts of immunocompromised adults, a demographic particularly vulnerable to severe respiratory syncytial virus (RSV)-associated lower respiratory tract disease (LRTD). During the study, a single dose of ABRYSVO produced a robust neutralizing response against both RSV subtypes, RSV-A and RSV-B, across all cohorts and age groups.
Moreover, ABRYSVO demonstrated good tolerability throughout the trial, maintaining a safety profile consistent with those observed in previous vaccine studies.
